Clinical trials: Myocardial Infarction
Primary Prevention of Atherosclerotic Cardiovascular Disease
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at…
- Trial name
- NCT05739383
- Testing
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Where
- 983 sites in United States, Argentina and 40 more
- Volunteers
- 14,012 people
- Sponsor
- Novartis Pharmaceuticals
Major Cardiovascular Event, Established Atherosclerotic Cardiovascular Disease
A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease
The primary objective of the study is to evaluate real-world effectiveness of treatment with Repatha® in combination with SOC, compared with SOC alone, on the risk for cardiovascular (CV) death, myocardial infarction (MI)…
- Trial name
- NCT06295679
- Where
- 90 sites in China
- Volunteers
- 7,000 people
- Sponsor
- Amgen
Cardiovascular Disease and Lipoprotein(a)
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)
- Trial name
- Lp(a)HORIZON (NCT04023552)
- Testing
- TQJ230
- Where
- 902 sites in United States, Argentina and 41 more
- Volunteers
- 8,323 people
- Sponsor
- Novartis Pharmaceuticals
Myocardial Infarction, Acute, Heart Failure, Left Sided
Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction
This is a Phase 2, multicenter, randomized, parallel, 3-arm, placebo-controlled study to assess efficacy and safety of CDR132L in patients with reduced Left Ventricular Ejection Fraction (LVEF) (≤ 45%) after myocardial infarction…
- Trial name
- HF-REVERT (NCT05350969)
- Testing
- CDR132L
- Where
- 49 sites in Czechia, Germany and 6 more
- Volunteers
- 294 people
- Sponsor
- Cardior Pharmaceuticals GmbH
Myocardial Infarction, Cardiogenic Shock
Efferon CT Hemoadsorption for Cardiogenic Shock in Acute Myocardial Infarction
Cardiogenic shock is the most severe manifestation of acute heart failure and remains the leading cause of death in patients hospitalised with acute myocardial infarction.
- Trial name
- NCT06955936
- Testing
- Efferon CT
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- Efferon JSC
Cardiovascular Disease
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for…
- Trial name
- NCT07136012
- Testing
- Olpasiran
- Where
- 252 sites in United States, Australia and 1 more
- Volunteers
- 11,000 people
- Sponsor
- Amgen
STEMI - ST Elevation Myocardial Infarction, AMI
SuperSaturated Oxygen Comprehensive Observational Registry
The SuperSaturated Oxygen Comprehensive Observational Registry (SSCORE) registry, a prospectively designed observational study, aims to evaluate the clinical utility, infarct size reduction, and cost-effectiveness of SSO2 Therapy…
- Trial name
- SSCORE (NCT06438315)
- Testing
- KCCQ, Eq5D, cMRI (Subset of patients)
- Where
- 25 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- TherOx
Segment Elevation Myocardial Infarction (STEMI)
NATURE (EnVast as an Adjunct PPCI in Subjects Presenting With STEMI)
This study is designed to compare the safety and effectiveness of blood clot (thrombus) removal in subjects presenting with ST-segment elevation myocardial infarction (STEMI) with the enVast coronary system versus conventional…
- Trial name
- NATURE (NCT04969471)
- Testing
- enVast stent, conventional treatment
- Where
- 11 sites in Italy, Netherlands and 1 more
- Volunteers
- 148 people
- Sponsor
- Vesalio
Coronary Artery Disease, Stable Angina
Validation of the MedHub AutocathFFR Software Device for Non-Invasive Fractional Flow Reserve (FFR)
This observational study evaluated how well the AutocathFFR software measures fractional flow reserve (FFR) from coronary angiogram images.
- Conditions
- Coronary Artery Disease, Stable Angina, Unstable Angina, Non-ST-Elevation Myocardial Infarction
- Trial name
- NCT07763769
- Testing
- MedHub AutocathFFR
- Where
- 4 sites in United States
- Volunteers
- 277 people
- Sponsor
- Medhub Ltd.
Myocardial Infarction
Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients
Evaluation of clinical outcomes during 12 months after inclisiran initiation in patients after STEMI/non-STEMI in real-world settings in Russia.
- Trial name
- STREAMLINE (NCT07142265)
- Where
- 18 sites in Russia
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myocardial Infarction
A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack
The goal of this study is to find out how fast a drug called selatogrel (ACT-246475) can prevent platelets from binding together. This study will also help to find out more about the safety of this new drug.
- Trial name
- NCT03487445
- Testing
- Selatogrel 8 mg, Selatogrel 16 mg
- Where
- 6 sites in Belgium, Israel and 1 more
- Volunteers
- 48 people
- Sponsor
- Viatris Innovation GmbH
Left Ventricular Dysfunction, Coronary Artery Disease
Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function
The purpose of this study is to assess if using the Impella® CP (or Impella® 2.5) device during high-risk PCI in patients with reduced left-sided heart function will result in an improvement in symptoms, heart function and health…
- Trial name
- PROTECT IV (NCT04763200)
- Testing
- Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
- Where
- 110 sites in United States, Canada and 5 more
- Volunteers
- 1,252 people
- Sponsor
- Abiomed Inc.
Myocardial Infarction
IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack
This study is open to adults aged 18 and over who have just had a heart attack. The purpose of this study is to find out whether a medicine called BI 765845 helps people who have had a heart attack.
- Trial name
- IRI-EXPLORE (NCT06139328)
- Testing
- BI 765845
- Where
- 53 sites in Australia, Canada and 12 more
- Volunteers
- 160 people
- Sponsor
- Boehringer Ingelheim
Acute Myocardial Infarction
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen et al. 2018) and having additional cardiovascular risk factors.
- Trial name
- SOS-AMI (NCT04957719)
- Testing
- Selatogrel
- Where
- 821 sites in United States, Australia and 43 more
- Volunteers
- 25,000 people
- Sponsor
- Viatris Innovation GmbH
Acute Myocardial Infarction (AMI)
Artificial Intelligence Scalable Solution for ST Myocardial Infarction
The ASSIST clinical study is an observational, multicenter study to assess the performance of a cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named Willem™, developed to detect Acute Myocardial Infarction…
- Trial name
- ASSIST (NCT06939738)
- Where
- 5 sites in Portugal, Spain
- Volunteers
- 489 people
- Sponsor
- Idoven 1903 S.L.
Cardiogenic Shock, Heart Failure
Magenta Elevate™ Clinical Feasibility Study in Cardiogenic Shock
The Elevate™ CS Clinical Feasibility Study is designed to evaluate the initial safety, effectiveness, and device performance of the Magenta Elevate™ System in patients with cardiogenic shock due to isolated or predominant left…
- Conditions
- Cardiogenic Shock, Heart Failure, Acute Myocardial Infarction (AMI)
- Trial name
- NCT07293923
- Testing
- Elevate™ System
- Where
- 8 sites in Georgia, Israel
- Volunteers
- 10 people
- Sponsor
- Magenta Medical Ltd.
Coronary Computed Tomographic Angiography, Myocardial Infarction (MI)
GSI Cardiac on Revolution Apex - US
The goal of this clinical data collection study is to collect raw CT scan data using a new GSI Cardiac mode on GE HealthCare's Revolution Apex CT system.
- Conditions
- Coronary Computed Tomographic Angiography, Myocardial Infarction (MI), Cardiac Catheterization
- Trial name
- NCT06702917
- Testing
- GSI Cardiac Scan, Standard of Care CCTA, Research CCTA
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- GE Healthcare
Acute Anterior ST-Segment Elevation Myocardial Infarction
A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction
This is a multicenter, randomized, double-blind, placebo-controlled, single-dose, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of SGC001 injection administered in addition to…
- Trial name
- NCT07306182
- Testing
- SGC001 injection
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Beijing Sungen Biomedical Technology Co., Ltd
Acute Coronary Syndromes (ACS), Recent Myocardial Infarction
The Pharmacokinetics and Pharmacodynamics Study of Evategrel CG-0255 Besylate）and Plavix® in Healthy Participants
CG-0255 is a novel investigational prodrug of the active metabolite of Plavix®， but with different active metabolite conversion routes.
- Conditions
- Acute Coronary Syndromes (ACS), Recent Myocardial Infarction, Recent Stroke, Peripheral Arterial Disease
- Trial name
- NCT07619885
- Testing
- CG-0255 Besylate for Injection, CG-0255 Besylate Capsule, Clopidogrel
- Where
- United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Shanghai CureGene Pharmaceutical Co., Ltd.
Myocardial Infarction
Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI
Safety and efficacy of adjunctive antiplatelet therapy prior to primary percutaneous intervention (PCI) in patients with ST-Elevation Myocardial Infarction (STEMI)
- Trial name
- ERASE-MI (NCT00546260)
- Testing
- PRT060128 Potassium
- Where
- 31 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Alexion Pharmaceuticals, Inc.